Search

Displaying results 6031 - 6040 of 6279 in total
  1. Drug

    IMM-101

    go.drugbank.com/drugs/DB15850
    Investigational

    It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023].

  2. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.

  3. Drug

    Deoxyribonuclease I

    go.drugbank.com/drugs/DB16523
    Investigational

    It is normally found in saliva, urine, pancreatic secretions, and blood[A227723].

  4. Drug

    MVA-BN-brachyury-TRICOM vaccine

    go.drugbank.com/drugs/DB17424
    Investigational

    of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3. … It is composed of recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a triad

  5. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    Because Hly is only active at an acidic pH, similar to listeriolysin O, the deletion of urease C was also beneficial for Hly to have optimal bioactivity in the phagosome. … VPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other

  6. Drug

    Rocatinlimab

    go.drugbank.com/drugs/DB18809
    Investigational

    In clinical trials, it has shown significant efficacy and safety compared to a placebo.

  7. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.

  8. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039.

  9. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    TM5614 inhibition of PAI-1, specifically, downregulates PCSK9 at the transcriptional level[A228793].

  10. Drug

    Ohmefentanyl

    go.drugbank.com/drugs/DB01570
    ExperimentalIllicit

    Ohmefentanyl has three stereogenic centers and hence, it can derive into eight stereoisomers, currently named F9201–F9208.